医学
脂肪变性
重症监护医学
疾病
药物治疗
脂肪肝
肝病
入射(几何)
改变生活方式
代谢紊乱
生物信息学
内科学
生物
物理
光学
作者
Amani Elshaer,David M. Chascsa,Blanca Lizaola‐Mayo
出处
期刊:Life
[MDPI AG]
日期:2024-07-03
卷期号:14 (7): 844-844
被引量:3
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI